The Accelerated Access Collaborative (AAC) is a partnership established in England to expedite the development and adoption of innovative health technologies within the National Health Service (NHS).
The National Agency for the Safety of Medicines and Health Products (Agence nationale de sécurité du médicament et des produits de santé, ANSM) plays a role in improving patient access to new therapies in France. By implementing regulatory procedures and offering scientific support, the agency aims to ensure timely access to treatments while maintaining safety and efficacy standards.
The European Union (EU) operates a set of research and innovation (R&I) programmes that provide indirect but substantial incentives for the development of innovative medicines.
The French government’s France 2030 plan is a national initiative to modernise health research, accelerate scientific discoveries, and improve patient care. It is led by the French Ministry of the Economy, Finance and Recovery (Ministère de l’Économie, des Finances et de la Relance, MEFR).
The head of the German physician association has called for major reforms to ensure that doctors are not held financially responsible for the high costs of innovative treatments.
German health bodies have agreed to new framework rules that shield physicians from financial penalties when prescribing innovative therapies and biosimilars.
The French National Authority for Health (Haute Autorité de Santé, HAS) has in place a structured action plan issued in 2020 to adopt evaluation processes for innovative medicines. The plan focuses on three core initiatives: issuing conditional opinions for early access, implementing real-world monitoring to confirm efficacy and safety, and streamlining assessments for high-value medicines.
Additional national funding for medicines in Italy is used mainly to support timely and consistent uptake of medicines that have been designated as ‘innovative’ for a specific indication, rather than to create a separate route that bypasses routine national pricing and reimbursement.
Italy’s main nationally defined mechanism to support access to innovative medicines is the innovativeness framework administered by the Italian Medicines Agency (Agenzia Italiana del Farmaco, AIFA).
The UK regulator has refined its national assessment procedure to offer a streamlined 150-day approval target for innovative medicines and more stringent technical submission standards.
